ArticlePloS one2018
Impact of structural prior knowledge in SNV prediction: Towards causal variant finding in rare disease.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Comparison of machine learning models for mucopolysaccharidosis early diagnosis using UAE medical records.Scientific reports · 2025Article
- d-StructMAn: Containerized structural annotation on the scale from genetic variants to whole proteomes.GigaScience · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Can structural information of proteins generate essential features for predicting the deleterious effect of a single nucleotide variant (SNV) independent of the known existence of the SNV in diseases? In this work, we answer the question by examining the performance of features generated from prior knowledge with the goal towards determining the pathogenic effect of rare variants in rare disease. We take the approach of prioritizing SNV loci focusing on protein structure-based features. The proposed structure-based features are generated from geometric, physical, chemical, and functional properties of the variant loci and structural neighbors of the loci utilizing multiple homologous structures. The performance of the structure-based features alone, trained on 80% of HumVar-HumDiv combination (HumVD-train) and tested on 20% of HumVar-HumDiv (HumVD-test), ClinVar and ClinVar rare variant rare disease (ClinVarRVRD) datasets, showed high levels of discernibility in determining the SNV's pathogenic or benign effects on patients. Combined structure- and sequence-based features generated from prior knowledge on a random forest model further improved the F scores to 0.84 (HumVD-test), 0.75 (ClinVar), and 0.75 (ClinVarRVRD). Including features based on the difference between wild-type in addition to the features based on loci information increased the F score slightly more to 0.90 (HumVD-test), 0.78 (ClinVar), and 0.76 (ClinVarRVRD). The empirical examination and high F scores of the results based on loci information alone suggest that location of SNV plays a primary role in determining functional impact of mutation and that structure-based features can help enhance the prediction performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.